Valeo Pharma Inc. (VPHIF)

OTCMKTS · Delayed Price · Currency is USD
0.000001
-0.000099 (-99.00%)
At close: Feb 11, 2026
Market Cap99.00 -100.0%
Revenue (ttm)38.64M -0.2%
Net Income-23.25M
EPS-0.26
Shares Out 98.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,000
Open0.000001
Previous Close0.0001
Day's Range0.000001 - 0.000001
52-Week Range0.000001 - 0.0003
Beta0.81
Analystsn/a
Price Targetn/a
Earnings Daten/a

About Valeo Pharma

Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization through all stages. The company offers access to product specialists and medical information for healthcare professionals and patients. Valeo Pharma se... [Read more]

Sector Healthcare
Founded 2003
Employees 70
Stock Exchange OTCMKTS
Ticker Symbol VPHIF
Full Company Profile

Financial Performance

In fiscal year 2023, Valeo Pharma's revenue was 53.91 million, an increase of 94.31% compared to the previous year's 27.75 million. Losses were -27.81 million, 8.01% more than in 2022.

Financial numbers in CAD Financial Statements

News

Valeo Pharma Earnings Call Transcript: Q3 2024

Q3 2024 revenues declined 11% year-over-year due to the loss of Xiidra, but core business grew 9% excluding Xiidra. Cost-saving measures improved adjusted EBITDA loss by 40%, and the company targets EBITDA positive in Q1 2025. REDESCA and respiratory units showed strong growth.

1 year ago - Transcripts

Valeo Pharma Earnings release: Q3 2024

Valeo Pharma released its Q3 2024 earnings on September 13, 2024, summarizing the period's financial results.

1 year ago - Filings

Valeo Pharma Earnings Call Transcript: Q2 2024

Q2 2024 saw record revenues and continued growth in core brands, despite a higher net loss driven by product mix and Xiidra's exit. Major restructuring aims to cut costs and support EBITDA breakeven by year-end, with strong momentum in respiratory and hospital segments.

2 years ago - Transcripts

Valeo Pharma Earnings release: Q2 2024

Valeo Pharma released its Q2 2024 earnings on June 14, 2024, summarizing the period's financial results.

2 years ago - Filings

Valeo Pharma Transcript: AGM 2024

2 years ago - Transcripts

Valeo Pharma Earnings release: Q1 2024

Valeo Pharma released its Q1 2024 earnings on March 15, 2024, summarizing the period's financial results.

2 years ago - Filings

Valeo Pharma Earnings release: Q4 2023

Valeo Pharma released its Q4 2023 earnings on January 30, 2024, summarizing the period's financial results.

2 years ago - Filings

Valeo Pharma Earnings release: Q3 2023

Valeo Pharma released its Q3 2023 earnings on September 14, 2023, summarizing the period's financial results.

2 years ago - Filings

Valeo Pharma Earnings release: Q2 2023

Valeo Pharma released its Q2 2023 earnings on June 14, 2023, summarizing the period's financial results.

3 years ago - Filings

Valeo Pharma Transcript: AGM 2023

3 years ago - Transcripts

Valeo Pharma Earnings release: Q1 2023

Valeo Pharma released its Q1 2023 earnings on March 16, 2023, summarizing the period's financial results.

3 years ago - Filings

Valeo Pharma Earnings release: Q4 2022

Valeo Pharma released its Q4 2022 earnings on January 31, 2023, summarizing the period's financial results.

3 years ago - Filings

Valeo Pharma Earnings release: Q3 2022

Valeo Pharma released its Q3 2022 earnings on September 14, 2022, summarizing the period's financial results.

4 years ago - Filings

VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for AR...

4 years ago - PRNewsWire

Valeo Pharma Transcript: Status update

4 years ago - Transcripts

Valeo Pharma Earnings release: Q2 2022

Valeo Pharma released its Q2 2022 earnings on June 15, 2022, summarizing the period's financial results.

4 years ago - Filings